*

REFLUXUL ESOFAGIAN

 

Boala de reflux gastro-esofagian (GERD=Gastro-Esophagial Reflux Disease) este o afectiune digestiva cronica caracterizata de relaxarea sfincterului esofagian inferior (si a muschilor aferenti), ceea ce permite o deplasare retrograda a continutului stomacului (mancare, acid stomacal si enzime digestive). Ea este o conditie foarte frecventa, in special in randul persoanelor care mananca inainte de culcare.  Cca 36-44% dintre adulti experimenteaza simptomele ei o data pe luna, cca 20% sufera frecvent (saptamanal) de simptomele ei si 7% sufera zilnic de pe urma acestei boli.

 

Simptomele sunt: arsuri la stomac – pirozis (perceput  ca o senzatie de arsura in spatele sternului), regurgitatie si   manifestari extraesofagiene: durere toracica noncardiaca, simptome pulmonare (tuse, astm, respiratie suieratoare,  pneumonie de aspiratie,  fibroza pulmonara), laringiene (raguseala, disfonie), faringiene (faringita), halitoza, sughit cronic, senzatie “nod in gat”), eroziuni dentare   – toate acestea agravandu-se dupa masa sau odata cu cresterea presiunii abdominale.

 

Factorii care declanseaza boala sunt: ciocolata (si orice aliment care contine cofeina), mancarurile prajite, alimentele picante sau grase, ceapa, usturoiul, citricele, menta, rosiile si pastele din rosii, alcoolul, fumatul, sarcina si obezitatea. Pentru a preveni declansarea bolii, este recomandat a se evita consumul de alimente cu 3 ore inainte de culcare, ridicarea capului patului, consumul de mese mici cantitativ si pierderea in greutate pentru persoanele cu exces de greutate.

 

 

Complicatiile GERD sunt urmatoarele:

• esofagita de reflux (esofagita peptica) – cel mai frecvent
• ulcer esofagian (poate determina hemoragie digestiva)
• stenoze esofagiene peptice aparute datorita fibrozarii ce determina constrictia lumenului esofagian (circa 10% dintre pacientii)
• esofag Barrett (leziune premaligna, cu risc de dezvoltare a adenocarcinomului esofagian)

 

Medicina alopata considera hernia hiatala si excesul de acid gastric drept cauza a GERD,  si ofera medicamente:

• antiacide : neutralizeaza acidului gastric refluat cu ameliorarea rapida a simptomatologiei
• antisecretorii : inhiba secretia acida gastrica – blocanti de H2 receptori si inhibitori de pompa de protoni

Utilizarea pe termen lung a medicatiei cu inhibitori ai pompei de protoni si antagonisti ai receptorilor de histamina H2 genereaza urmatoarele efecte adverse:

• afecteaza absorbtia nutrientilor, generand deficite nutritionale ce pot avea consecinte severe:  magneziul este cel mai afectat, ceea ce creste riscul afectiunilor cardiovasculare (boala coronariana, hipertensiune, tulburare agregare plachetara), fracturii de sold (Corley 2010), bolii Alzheimer etc
• reducerea acidului gastric sustine infiltrarea/ dezvoltarea microblor gen Helicobacter, Candida etc care contribuie la dezvoltarea ulcerului, aterosclerozei, bolilor autoimune etc.

 

Medicina functionala considera drept cauze ale bolii  de reflux gastroesofagian urmatoarele:

• disfunctia nervilor (neuropatia) ce actioneaza asupra muschilor sfincterului esofagian inferior (lipsa contractare – peste 50% din cazuri),
• infectia cu helicobacter (cca 40% din cazuri),
• hipoclorhidria (implicata si in infectia H. – teorie Wright, 2001),
• medicamente ce relaxeaza sfincterul:  medicamente  blocante ale canalelor de calciu (anti-hipertensive care relaxeaza peretele arterial   - si miocardul) si medicamente anti-colinergice: anti-histaminice, relaxante ale musculaturii netede (Debridat, Colospasm, Captopril, Nifedipin etc) sau dorsale, bronho-dilatatoarele, anti-depresivele ciclice, med. anti-tulburari gastro-intestinale (Ranitidina) etc

 

SUPORTUL INFO-ENERGETIC

Noi consideram ca terapia corecta a refluxului esofagian implica adresarea cauzelor existente, intarirea sfincterului esofagian si vindecarea tesutului de ulceratii.

Suportul informational cuprinde evaluarea energetica functionala ce investigheaza cauzele posibile (dezechilibru acid gastric, infectie Helicobacter pylori, neuropatie, stres emotional, alergii, probleme colescit etc- nu cauzele medicamentoase !), consecintele existente la nivelul esofagului, faringelui, plamanilor etc.

Suportul energetic  urmareste sa adreseze cauzele constatate, sa reduca inflamatia si sa cicatrizeze tesuturile, printr-o combinatie personalizata de terapii ce cuprinde:  biorezonanta, biofeedback, Rife,  imagerie ghidata etc.

 

 

REFERINTE:

• “The use of resonance-frequency diagnostics for heliobacteriosis in children’s gastroduodenitises” – Leskin G.S., Petritskaja E.N., Ursova N.I., Gotovskiy Ju.V.  (M.F. Vladimirskiy MRSRCI, Center «IMEDIS» Moscow, Russia) – Proceedings of the X International Conference “Theoretical and clinical aspects of application of bioresonance and multiresonance therapy”
• “Principles of treating chronic gastrointestinal tract pathology by bioresonance therapy with application of vegetative resonance test” – Bukarev A.A. (St.Petersburg, Russia)  – Proceedings of the V International Conference “Theoretical and clinical aspects of application of bioresonance and multiresonance therapy”
• “Efficiency of energyinformational diagnostic and therapy for diseases of gastro-intestinal tract” – Maslova M.G., Volodarskiy V.L., Bobrovich L.N., Druchilo T.F.  (National SRC OT & VB Ukraine, Kiev, Ukraine) – Proceedings of the VIII International Conference “Theoretical and clinical aspects of application of bioresonance and multiresonance therapy”
• “The use of nosode free electropunctural diagnostics by R.Voll’s method in gastroenterology” – Kobilianskaia R.N., Kobilianski V.Y. (SRI for informtherapy,  Kiev, CDC “Infatep-Plus”, Kolomiya, Ukraine) – Proceedings of the VIII International Conference “Theoretical and clinical aspects of application of bioresonance and multiresonance therapy”
• “Energyinfoarmation methods and their capabilities in formation  of individual treatment schemes for gastroenterological patients” – Swmwndyaeva M.E., Aleshina T.V., Bakulina I.F., Zhuravleva M.G., Pastukhov A.I. (Clinical hospital №83 Medbioextrem, Moscow, Russia)  – Proceedings of the XI International Conference “Theoretical and clinical aspects of application of bioresonance and multiresonance therapy”
• “The Diaphragm Biofeedback Training In Treatment Of Gastroesophageal Reflux Disease, Efficacy And Mechanism Study” -  teza doctorat H Wu (China), 2010 - http://www.globethesis.com/?t=1114360305467858
• “A Comparison of Factors of Symptoms Generation and Evaluation of Role of Biofeedback in Patients With Different Types of Functional Esophageal Disorders (Functional Heartburn and Functional Chest Pain”- Assaf-Harofeh Medical Center

• “Clinical curative effect of electroacupuncture combined with zhizhukuanzhong capsules for treating gastroesophageal reflux disease”  – Chaoxian Zhang, Like Guo, Xiaofeng Guo, Xiaohe Guo, Guangyan Li (The First Affiliated Hospital of Xinxiang Medical University, China)  -  Journal of Traditional Chinese Medicine   (Impact Factor: 0.59).   09/2012; 32(3):364-71.
• “Clinical applications of Electro-Acupuncture” – Dr. Yang – Florida College of Integrative Medicine
• “Omeprazole decreases magnesium transport across Caco-2 monolayers” – Thongon N, et al – World J Gastroent, 17; 12:1574-83, March 28, 2011
• “Proton-pump inhibitors and hypomagnesemic hyperparathyroidism” – Epstein M., et al – New Engl J Med, 355:18 34-36, 2006
• “Omeprazole and refractory hypomagnesemia” – Shabajee N, et al – Brit Med J 337:80 425, 2008
• “Severe hypomagnesemia in long-term users of proton-pump inhibitors” – Cundy T, et al – Clin Endocrinol (Oxford) 69:338-41,2008
• “Hypo-magnesemia induced by several proton- pump inhibitors” – Broeren MA, et al – Ann Intern Med 151:755-6, 2009
• “Baseline proton pump inhibitor use is associated with increased cardiovascular events with and without the use of clopidogrel in the CRDEO trial” -  Dunn SP. et at – Circulation 118: S8I5, abst. 2008
• “Risk of adverse outcomes associated with concomitant use of clopidogrel and proton pump inhibitors following acute coronary syndrome” – Ho PM, et at, -  J Am Med Assoc 301:937-44, 2009
• “Role of magnesium in the pathogenesis of hypertension” – Touyz RM  – Mol Aspects Med 24:107-36, 2003